Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis
Background/Aims: Whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) could benefit patients with diabetes and albuminuria remains controversial. A systematic review and meta-analysis were conducted to answer this question by comparing ACE inhibitors or AR...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2018-05-01
|
Series: | Kidney & Blood Pressure Research |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/489913 |
id |
doaj-316d4869e7e7466c848d53681e1e7f5e |
---|---|
record_format |
Article |
spelling |
doaj-316d4869e7e7466c848d53681e1e7f5e2020-11-25T03:19:04ZengKarger PublishersKidney & Blood Pressure Research1420-40961423-01432018-05-0143376877910.1159/000489913489913Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-AnalysisKanran WangJinbo HuTing LuoYue WangShumin YangHua QingQingfeng ChengQifu LiBackground/Aims: Whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) could benefit patients with diabetes and albuminuria remains controversial. A systematic review and meta-analysis were conducted to answer this question by comparing ACE inhibitors or ARB with placebo among these patients. Methods: In this meta-analysis, electronic data sources (Medline, the Cochrane Collaboration, and EMBASE) were searched. Randomized controlled trials (RCTs) comparing ACE inhibitors or ARB with placebo in subjects with diabetes and albuminuria (defined as urinary albumin-to-creatinine ratio, UACR≥30mg/g Cr) were included. Outcomes parameters were all-cause mortality, end stage renal disease (ESRD), doubling of serum creatinine levels, and cardiovascular events (CV). Results: Twenty-six RCTs (including 20 for ACE inhibitors and 6 for ARB) were included, comprising 10378 participants with diabetes and albuminuria. Compared to placebo, treatment with ACE inhibitors or ARBs did not reduce all-cause mortality or CV. For renal outcomes, ARBs significantly reduced the risk of ESRD by 23% (odds ratio 0.77, 95%CI 0.65-0.92), while ACE inhibitors were not associated with a decreased risk of ESRD (0.69, 0.43-1.10). Both ACE inhibitors and ARBs reduced the risk of doubling of the serum creatinine level (0.60, 0.39-0.91 for ACE inhibitors; 0.75, 0.64-0.88 for ARBs), and subgroup analyses for patients with macroalbuminuria or microalbuminuria showed similar results. Conclusion: In patients with diabetes and albuminuria, ARBs reduced risks of ESRD and doubling of the serum creatinine level. ACE inhibitors and ARBs failed to reduce all-cause mortality and CV. Based on the renoprotective effects, ARBs may be preferred for diabetic patients with albuminuria.https://www.karger.com/Article/FullText/489913Albuminuria regressionAll-cause mortalityAngiotensin II receptor blockersAngiotensin-converting enzyme(ACE) inhibitorsDoubling of serum creatinineEnd-stage renal diseaseMacroalbuminuriaMeta-analysisMicroalbuminuriaReno-protective effectDiabetes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kanran Wang Jinbo Hu Ting Luo Yue Wang Shumin Yang Hua Qing Qingfeng Cheng Qifu Li |
spellingShingle |
Kanran Wang Jinbo Hu Ting Luo Yue Wang Shumin Yang Hua Qing Qingfeng Cheng Qifu Li Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis Kidney & Blood Pressure Research Albuminuria regression All-cause mortality Angiotensin II receptor blockers Angiotensin-converting enzyme(ACE) inhibitors Doubling of serum creatinine End-stage renal disease Macroalbuminuria Meta-analysis Microalbuminuria Reno-protective effect Diabetes |
author_facet |
Kanran Wang Jinbo Hu Ting Luo Yue Wang Shumin Yang Hua Qing Qingfeng Cheng Qifu Li |
author_sort |
Kanran Wang |
title |
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis |
title_short |
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis |
title_full |
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis |
title_fullStr |
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis |
title_full_unstemmed |
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis |
title_sort |
effects of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis |
publisher |
Karger Publishers |
series |
Kidney & Blood Pressure Research |
issn |
1420-4096 1423-0143 |
publishDate |
2018-05-01 |
description |
Background/Aims: Whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) could benefit patients with diabetes and albuminuria remains controversial. A systematic review and meta-analysis were conducted to answer this question by comparing ACE inhibitors or ARB with placebo among these patients. Methods: In this meta-analysis, electronic data sources (Medline, the Cochrane Collaboration, and EMBASE) were searched. Randomized controlled trials (RCTs) comparing ACE inhibitors or ARB with placebo in subjects with diabetes and albuminuria (defined as urinary albumin-to-creatinine ratio, UACR≥30mg/g Cr) were included. Outcomes parameters were all-cause mortality, end stage renal disease (ESRD), doubling of serum creatinine levels, and cardiovascular events (CV). Results: Twenty-six RCTs (including 20 for ACE inhibitors and 6 for ARB) were included, comprising 10378 participants with diabetes and albuminuria. Compared to placebo, treatment with ACE inhibitors or ARBs did not reduce all-cause mortality or CV. For renal outcomes, ARBs significantly reduced the risk of ESRD by 23% (odds ratio 0.77, 95%CI 0.65-0.92), while ACE inhibitors were not associated with a decreased risk of ESRD (0.69, 0.43-1.10). Both ACE inhibitors and ARBs reduced the risk of doubling of the serum creatinine level (0.60, 0.39-0.91 for ACE inhibitors; 0.75, 0.64-0.88 for ARBs), and subgroup analyses for patients with macroalbuminuria or microalbuminuria showed similar results. Conclusion: In patients with diabetes and albuminuria, ARBs reduced risks of ESRD and doubling of the serum creatinine level. ACE inhibitors and ARBs failed to reduce all-cause mortality and CV. Based on the renoprotective effects, ARBs may be preferred for diabetic patients with albuminuria. |
topic |
Albuminuria regression All-cause mortality Angiotensin II receptor blockers Angiotensin-converting enzyme(ACE) inhibitors Doubling of serum creatinine End-stage renal disease Macroalbuminuria Meta-analysis Microalbuminuria Reno-protective effect Diabetes |
url |
https://www.karger.com/Article/FullText/489913 |
work_keys_str_mv |
AT kanranwang effectsofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersonallcausemortalityandrenaloutcomesinpatientswithdiabetesandalbuminuriaasystematicreviewandmetaanalysis AT jinbohu effectsofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersonallcausemortalityandrenaloutcomesinpatientswithdiabetesandalbuminuriaasystematicreviewandmetaanalysis AT tingluo effectsofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersonallcausemortalityandrenaloutcomesinpatientswithdiabetesandalbuminuriaasystematicreviewandmetaanalysis AT yuewang effectsofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersonallcausemortalityandrenaloutcomesinpatientswithdiabetesandalbuminuriaasystematicreviewandmetaanalysis AT shuminyang effectsofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersonallcausemortalityandrenaloutcomesinpatientswithdiabetesandalbuminuriaasystematicreviewandmetaanalysis AT huaqing effectsofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersonallcausemortalityandrenaloutcomesinpatientswithdiabetesandalbuminuriaasystematicreviewandmetaanalysis AT qingfengcheng effectsofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersonallcausemortalityandrenaloutcomesinpatientswithdiabetesandalbuminuriaasystematicreviewandmetaanalysis AT qifuli effectsofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersonallcausemortalityandrenaloutcomesinpatientswithdiabetesandalbuminuriaasystematicreviewandmetaanalysis |
_version_ |
1724623893988114432 |